Salt Lake City April 8 2009 -- Myriad Pharmaceuticals Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor MPC-3100 for the treatment of cancer. The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase 1 trial will assess the safety and pharmacokinetics profile of MPC-3100.

Part 1 – Introducing “IBD (Crohn's Disease/ulcerative colitis)” and “Mabs”Inflammatory bowel disease (IBD) describes the spectrum of chronic intestinal inflammation from Crohn's disease to ulcerative colitis Although this term is very misleading (because there are mUCh more diseases which also imply intestinal inflammation such as infective diarrhea for example) Inflammatory bowel disease is universally used as synonym of the Crohn's Disease/ulcerative colitis pair.IBD seems to occur as a consequence of a persistent and inappropriate immunologic response to gut luminal antigens.